ClinicalTrials.gg
RecruitingNCT05174169CIRCULATE-USUpdated Nov 4, 2026

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

A Phase 2/3 interventional study of Signatera test and mFOLFOX6 3-6 month in Stage III Colon Cancer, sponsored by NRG Oncology. Recruiting at 1,085 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by NRG Oncology · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.
Updated Nov 4, 2026Site recruiting status changed12 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,912
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.

Planned enrollment
47th of 865
1,912 · median 50
Started
2022
with 45 others
Phase 2/3
6 of 1,123
1 open now
Primary completion
2029-03
later than 143 of 187 live
Registered
954th of 1,123
by date

Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 47th largest by planned enrollment of the 865 interventional ones that give a count, is one of 46 that started in 2022, is one of 6 in phase 2/3, reaches primary completion later than 143 of the 187 other live ones, and was the 954th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

110 more — sign in →

All 115 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,123 studies in Colonic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Read the detailed description

Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer to determine need for adjuvant chemotherapy. However, circulating tumor DNA (ctDNA) shed into the bloodstream represents a highly specific and sensitive approach (especially with serial monitoring) for identifying microscopic or residual tumor cells in colon cancer patients and may outperform traditional clinical and pathological features in prognosticating risk for recurrence. Colon cancer patients who do not have detectable ctDNA (ctDNA-) are at a much lower risk of recurrence and may not need adjuvant chemotherapy. Furthermore, for colon cancer pts with detectable ctDNA (ctDNA+) who are at a very high risk of recurrence, the optimal adjuvant chemotherapy regimen has not been established. We hypothesize that for pts whose colon cancer has been resected, ctDNA status may be used to risk stratify for making decisions about adjuvant chemotherapy.

03

Conditions studied

  • Stage III Colon Cancer

Browse trials for

Keywords

  • ctDNA positive
  • ctDNA negative
  • Adjuvant Chemotherapy
  • Natera
  • Signatera
  • mFOLFOX6
  • Stage III
  • CAPOX
  • mFOLFIRINOX
  • Oxaliplatin
  • 5-Fluorouracil (5-FU)
  • Capecitabine
  • Leucovorin
  • Irinotecan
  • Stage II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The patient must have an performance status of 0 or 1.

Patients must have histologically/ confirmed Stage IIB, IIC, or Stage III colon adenocarcinoma with R0 resection according to AJCC 8th edition criteria.

No radiographic evidence of overt disease within 45 days prior to Step 1/Study entry (CT with IV contrast or MRI imaging is acceptable and must include chest, abdomen, and pelvis).

The distal extent of the tumor must be greater than or equal to 12 cm from the anal verge on colonoscopy or above the peritoneal reflection as documented during surgery or on pathology specimen (i.e., excluding rectal adenocarcinomas warranting treatment with chemoradiation).

The patient must have had an en bloc complete gross resection of tumor (curative resection). Patients who have had a two-stage surgical procedure, to first provide a decompressive colostomy and then in a later procedure to have the definitive surgical resection, are eligible.

The resected tumor specimen and a blood specimen from patients with Stage IIB, IIC, or Stage III colon cancer must have central testing for ctDNA using the Signatera™ assay by Natera (after Step 1/Study entry and before Step2/Randomization). Patient must have sufficient tissue to meet protocol requirements. This blood specimen for the Signatera assay must be collected after surgery (and recommended at least 14 days post surgery).

Tumor must be documented as microsatellite stable or have intact mismatch repair proteins through CLIA-approved laboratory testing. Patients whose tumors are MSI-H or dMMR are excluded.

The treating investigator must deem the patient a candidate for all potential agents used in this trial (5FU, LV, oxaliplatin and irinotecan).

The interval between surgery (post-operative Day 7) and Step 1/Study entry must be no more than 60 days. NOTE: Step 1/Study Entry may occur as early as post operative Day 7, but it cannot occur beyond 60 days from the actual date of the patient's surgery.

Availability and provision of adequate surgical tumor tissue for molecular diagnostics and confirmatory profiling.

Adequate hematologic function within 28 days before Step 1/Study entry defined as follows:

  • (ANC) must be greater than or equal to 1500/mm3;
  • Participants with benign ethnic neutropenia (BEN): ANC less than 1300 mm3 are eligible.
  • BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.
  • count must be greater than or equal to 100,000/mm3; and
  • must be greater than or equal to 9 g/dL.

Adequate hepatic function within 28 days before Step 1/Study entry defined as follows:

  • total must be less than or equal to (upper limit of normal) for the lab and
  • alkaline phosphatase must be less than 2.5 x ULN for the lab; and
  • and ALT must be less than 2.5 x ULN for the lab.

Adequate renal function within 28 days before Step 1/Study entry defined as serum creatinine less than or equal to 1.5 x ULN for the lab or measured or calculated greater than or equal to 50 mL/min using the Cockroft-Gault formula for patients with creatinine levels greater than 1.5 x ULN for the lab.

For Women Creatinine Clearance (mL/min) = (140 - age) x weight (kg) x 0.85 72 x serum creatinine (mg/dL) For Men Creatinine Clearance (mL/min) = (140 - age) x weight (kg) 72 x serum creatinine (mg/dL) NOTE: Adjusted body weight (AdjBW) should be used for patients that have greater than or equal to 28 (less than or equal to 30% above IBW).

-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

Pregnancy test (urine or serum according to institutional standard) done within 14 days before Step 1/Study entry must be negative (for women of only).

Patients receiving a coumarin-derivative anticoagulant must agree to weekly monitoring of if they are randomized to Arm 1 or Arm 3 and receive capecitabine.

Eligibility Criteria for Cohort A Arm-2 patients on Second Randomization

Patient must have developed a ctDNA +ve assay during serial monitoring.

Patient's willingness to be re-randomized affirmed.

The patient must continue to have an ECOG performance status of 0 or 1.

No radiographic evidence of overt metastatic disease.

Pregnancy test (urine or serum according to institutional standard) done within 14 days before second randomization must be negative (for women of childbearing potential only).

Adequate hematologic function within 28 days before second randomization defined as follows:

  • Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;
  • Participants with benign ethnic neutropenia (BEN): ANC less than 1300 mm3 are eligible.
  • BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.
  • Platelet count must be greater than or equal to 100,000/mm3; and
  • Hemoglobin must be greater than or equal to 9 g/dL.

Adequate hepatic function within 28 days before second randomization defined as follows:

  • total bilirubin must be less than or equal to ULN (upper limit of normal) for the lab and
  • alkaline phosphatase must be less than 2.5 x ULN for the lab; and
  • AST and ALT must be less than 2.5 x ULN for the lab.

Adequate renal function within 28 days before second randomization defined as serum creatinine less than or equal to 1.5 x ULN for the lab or measured or calculated creatinine clearance greater than or equal to 50 mL/min using the Cockroft-Gault formula for patients with creatinine levels greater than 1.5 x ULN for the lab.

For Women Creatinine Clearance (mL/min) = (140 - age) x weight (kg) x 0.85 72 x serum creatinine (mg/dL) For Men Creatinine Clearance (mL/min) = (140 - age) x weight (kg) 72 x serum creatinine (mg/dL)

Exclusion criteria

Exclusion Criteria:

Colon cancer histology other than adenocarcinoma (i.e., neuroendocrine carcinoma, sarcoma, lymphoma, squamous cell carcinoma, etc.).

Pathologic, clinical, or radiologic overt evidence of disease. This includes isolated, distant, or non-contiguous intra-abdominal metastases, even if resected.

Tumor-related bowel perforation.

History of prior invasive colon , regardless of disease-free interval.

History of bone marrow or solid organ transplantation (regardless of current therapy needs). Bone grafts, skin grafts, corneal transplants and organ/tissue donation are not exclusionary.

Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer (e.g., primary colon adenocarcinomas for which treatment with chemotherapy and/or radiation is warranted are not permitted). EXCEPTION: one cycle of chemotherapy (regimen per treating physicians' discretion - 5-FU or capecitabine with or without oxaliplatin) is allowed but not required after consent. The optional cycle of chemotherapy should be started greater than or equal to 4 weeks from surgery and while awaiting Step 2 randomization.

Other invasive malignancy within 5 years before Step 1/Study entry. Exceptions are colonic polyps, non-melanoma skin cancer or any carcinoma-in-situ.

Synchronous primary rectal and/ or colon cancers.

Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class 2B or better.

Sensory or motor neuropathy greater than or equal to grade 2, according to v5.0.

Blood transfusion within two weeks before collection of blood for central ctDNA testing.

Active seizure disorder uncontrolled by medication.

Active or chronic infection requiring systemic therapy.

Known homozygous DPD (dihydropyrimidine dehydrogenase) deficiency.

Patients known to have Gilbert's Syndrome or homozygosity for UGT1A1*28 polymorphism.

Pregnancy or lactation at the time of Step 1/Study entry.

Co-morbid illnesses or other concurrent disease that would make the patient inappropriate for entry into this study (i.e., unable to tolerate 6 months of combination chemotherapy or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens or prevent required follow-up).

Ineligibility Criteria for Cohort A Arm-2 patients on Second Randomization

Pregnancy or lactation at the time of randomization.

No longer a candidate for systemic chemotherapy (FOLFOX, CAPOX, and mFOLFIRINOX) in the opinion of the treating investigator.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,912 participants (estimated)

Study arms

  • Active comparator
    Cohort A - Arm 1 (ctDNA-ve)

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles OR Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles

    Device: Signatera test · Drug: mFOLFOX6 3-6 month · Drug: CAPOX 3 month

  • Experimental
    Cohort A - Arm 2 (ctDNA-ve)

    Serial ctDNA monitoring no treatment

    Device: Signatera test

  • Active comparator
    Cohort B - Arm 3 (ctDNA+ve)

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles OR Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles

    Device: Signatera test · Drug: mFOLFOX6 6 month · Drug: CAPOX 6 month

  • Experimental
    Cohort B - Arm 4 (ctDNA+ve)

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles

    Device: Signatera test · Drug: mFOLFIRINOX

Interventions

  • DeviceSignatera test

    Central ctDNA testing for all patients

  • DrugmFOLFOX6 3-6 month

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 6-12 cycles

  • DrugCAPOX 3 month

    Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 4 cycles

  • DrugmFOLFIRINOX

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + Irinotecan 150 mg/m2 IV continuous infusion (30-90 minutes) + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles

  • DrugmFOLFOX6 6 month

    Oxaliplatin 85 mg/m2 IV + Leucovorin 400mg/m2 IV + 5-Fluorouracil (5-FU) 400mg/m2 bolus + 5-Fluorouracil (5-FU) 2400mg/m2 IV continuous infusion over 46-48 hours (total dose) Day1 every 2 weeks for 12 cycles

  • DrugCAPOX 6 month

    Oxaliplatin 130 mg/m2 IV Day 1 every 3 weeks + Capecitabine 1000 mg/m2 BID by mouth days 1-14 every 3 weeks for 8 cycles

06

What researchers measure

Primary outcomes

  1. ctDNA positive status (TTPos)

    TTPos is defined as time from randomization until ctDNA positive event: TTPos events are first ctDNA positive result after randomization for the immediate adjuvant chemo arm (Arm 1), 2nd ctDNA positive result after randomization for the delayed adjuvant chemo (Arm 2) and recurrence without a positive ctDNA result for both arms.

    Time frame: Time from randomization to the first TTPos event, a maximum of 3 years

  2. Disease-Free Survival (DFS)

    Time from randomization to first disease-free survival event (recurrence, second primary colorectal cancer or death from any cause).

    Time frame: Time from randomization to disease-free survival event, a maximum of 5 years]

Secondary outcomes

  1. Baseline post-surgery ctDNA positivity rate

    percentage of patients with ctDNA positive results post-surgery at study entry.

    Time frame: At time of randomization

  2. Overall Survival (OS)

    Time from randomization to death of any cause.

    Time frame: Time from randomization to death, a maximum of 5 years.

  3. Recurrence

    Time from randomization to disease recurrence.

    Time frame: Time from randomization to disease recurrence, a maximum of 5 years

  4. Compliance with adjuvant chemotherapy

    number of cycles of chemotherapy received.

    Time frame: from randomization to the last cycle of chemotherapy, a maximum of 6 months.

07

Study locations

964 of 1,085 sites recruiting

Showing the first 100 of 1,085 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Mar 2029, 80 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Dec 30, 2021
StartActual
Jul 8, 2022
Primary completionEst.
Mar 10, 2029
CompletionEst.
Mar 10, 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 4 sites removed. 19 sites changed recruiting status (8 now suspended, 6 now recruiting, …)
Show 19 sites
  • Thomas Hospital · Fairhope, United StatesRecruiting→Suspended
  • Mobile Infirmary Medical Center · Mobile, United StatesRecruiting→Suspended
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United StatesRecruiting→Active, not recruiting
  • UC San Diego Moores Cancer Center · La Jolla, United StatesSuspended→Recruiting
  • UCI Health Laguna Hills · Laguna Hills, United StatesRecruiting→Active, not recruiting
  • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United StatesRecruiting→Active, not recruiting
  • UC San Diego Medical Center - Hillcrest · San Diego, United StatesSuspended→Recruiting
  • Rush-Copley Medical Center · Aurora, United StatesRecruiting→Suspended
  • Rush-Copley Healthcare Center · Yorkville, United StatesRecruiting→Suspended
  • Greater Regional Medical Center · Creston, United StatesRecruiting→Suspended
  • Trinity Health Muskegon Hospital · Muskegon, United StatesRecruiting→Suspended
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesSuspended→Recruiting
  • Monticello Cancer Center · Monticello, United StatesRecruiting→Suspended
  • Wake Forest University Health Sciences · Winston-Salem, United StatesRecruiting→Active, not recruiting
  • ProHealth D N Greenwald Center · Mukwonago, United StatesSuspended→Recruiting
  • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesSuspended→Recruiting
  • UW Cancer Center at ProHealth Care · Waukesha, United StatesSuspended→Recruiting
  • Windsor Regional Cancer Centre · Windsor, CanadaSuspended→Active, not recruiting
  • Hotel-Dieu De Levis · Lévis, CanadaRecruiting→Suspended
Show 12 added (11 United States, 1 Puerto Rico)
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis · Daphne, United States
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland · Saraland, United States
  • Tift Regional Medical Center · Tifton, United States
  • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
  • Virtua Samson Cancer Center · Moorestown, United States
  • Virtua Voorhees · Voorhees Township, United States
  • University of North Carolina-Hillsborough Campus · Hillsborough, United States
  • Avon - Richard E Jacobs Health Center · Avon, United States
  • Geisinger Cancer Center Dickson City · Dickson City, United States
  • Saint Anne Hospital · Burien, United States
  • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
  • Pan American Center for Oncology Trials LLC · San Juan, Puerto Rico
Show 4 removed
  • Newland Medical Associates-Pontiac · Pontiac, United States
  • Highline Medical Center-Main Campus · Burien, United States
  • West Virginia University Charleston Division · Charleston, United States
  • Pan American Center for Oncology Trials LLC - Mayaguez · San Juan, Puerto Rico
Nov 4, 2026
Site contacts
Changed at 77 sites. See the sites
Show 77 sites
  • Thomas Hospital · Fairhope, United StatesContact removed •••4584Contact removed (no phone or email listed)
  • Mobile Infirmary Medical Center · Mobile, United StatesContact removed •••3942Contact removed (no phone or email listed)
  • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
  • Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United StatesContact removed u•••@uci.edu · •••8839Contact removed (no phone or email listed)
  • UC San Diego Moores Cancer Center · La Jolla, United StatesContact added c•••@ucsd.edu · •••5354Contact added (no phone or email listed)
  • UCI Health Laguna Hills · Laguna Hills, United StatesContact removed u•••@uci.edu · •••8839Contact removed (no phone or email listed)
  • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United StatesContact removed u•••@uci.edu · •••8839Contact removed (no phone or email listed)
  • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
  • UC San Diego Medical Center - Hillcrest · San Diego, United StatesContact added r•••@health.ucsd.eduContact added (no phone or email listed)
  • Pacific Central Coast Health Center-San Luis Obispo · San Luis Obispo, United StatesContact person changed (no phone or email listed)
  • Mission Hope Medical Oncology - Santa Maria · Santa Maria, United StatesContact person changed (no phone or email listed)
  • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
  • Penrose-Saint Francis Healthcare · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • Rocky Mountain Cancer Centers-Penrose · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • Saint Francis Cancer Center · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • CommonSpirit Cancer Center Mercy · Durango, United StatesContact person changed (no phone or email listed)
  • Mercy Medical Center · Durango, United StatesContact person changed (no phone or email listed)
  • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United StatesContact person changed (no phone or email listed)
  • Longmont United Hospital · Longmont, United StatesContact person changed (no phone or email listed)
  • Saint Mary Corwin Medical Center · Pueblo, United StatesContact person changed (no phone or email listed)
  • Rush-Copley Medical Center · Aurora, United StatesContact removed R•••@rush.edu · •••6212Contact removed (no phone or email listed)
  • Loyola University Medical Center · Maywood, United StatesContact person changed (no phone or email listed)
  • Rush-Copley Healthcare Center · Yorkville, United StatesContact removed C•••@rushcopley.com · •••6212Contact removed (no phone or email listed)
  • Greater Regional Medical Center · Creston, United StatesContact removed •••3305Contact removed (no phone or email listed)
  • CommonSpirit Saint Joseph Hospital - Bardstown · Bardstown, United StatesContact person changed (no phone or email listed)
  • …and 47 more sites
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    12 sites added, 4 sites removed. 19 sites changed recruiting status (8 now suspended, 6 now recruiting, …)
    Show 19 sites
    • Thomas Hospital · Fairhope, United StatesRecruiting→Suspended
    • Mobile Infirmary Medical Center · Mobile, United StatesRecruiting→Suspended
    • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United StatesRecruiting→Active, not recruiting
    • UC San Diego Moores Cancer Center · La Jolla, United StatesSuspended→Recruiting
    • UCI Health Laguna Hills · Laguna Hills, United StatesRecruiting→Active, not recruiting
    • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United StatesRecruiting→Active, not recruiting
    • UC San Diego Medical Center - Hillcrest · San Diego, United StatesSuspended→Recruiting
    • Rush-Copley Medical Center · Aurora, United StatesRecruiting→Suspended
    • Rush-Copley Healthcare Center · Yorkville, United StatesRecruiting→Suspended
    • Greater Regional Medical Center · Creston, United StatesRecruiting→Suspended
    • Trinity Health Muskegon Hospital · Muskegon, United StatesRecruiting→Suspended
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesSuspended→Recruiting
    • Monticello Cancer Center · Monticello, United StatesRecruiting→Suspended
    • Wake Forest University Health Sciences · Winston-Salem, United StatesRecruiting→Active, not recruiting
    • ProHealth D N Greenwald Center · Mukwonago, United StatesSuspended→Recruiting
    • ProHealth Oconomowoc Memorial Hospital · Oconomowoc, United StatesSuspended→Recruiting
    • UW Cancer Center at ProHealth Care · Waukesha, United StatesSuspended→Recruiting
    • Windsor Regional Cancer Centre · Windsor, CanadaSuspended→Active, not recruiting
    • Hotel-Dieu De Levis · Lévis, CanadaRecruiting→Suspended
    Show 12 added (11 United States, 1 Puerto Rico)
    • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis · Daphne, United States
    • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland · Saraland, United States
    • Tift Regional Medical Center · Tifton, United States
    • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
    • Virtua Samson Cancer Center · Moorestown, United States
    • Virtua Voorhees · Voorhees Township, United States
    • University of North Carolina-Hillsborough Campus · Hillsborough, United States
    • Avon - Richard E Jacobs Health Center · Avon, United States
    • Geisinger Cancer Center Dickson City · Dickson City, United States
    • Saint Anne Hospital · Burien, United States
    • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
    • Pan American Center for Oncology Trials LLC · San Juan, Puerto Rico
    Show 4 removed
    • Newland Medical Associates-Pontiac · Pontiac, United States
    • Highline Medical Center-Main Campus · Burien, United States
    • West Virginia University Charleston Division · Charleston, United States
    • Pan American Center for Oncology Trials LLC - Mayaguez · San Juan, Puerto Rico
    Site contacts Changed at 77 sites. See the sites
    Show 77 sites
    • Thomas Hospital · Fairhope, United StatesContact removed •••4584Contact removed (no phone or email listed)
    • Mobile Infirmary Medical Center · Mobile, United StatesContact removed •••3942Contact removed (no phone or email listed)
    • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
    • Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
    • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, United StatesContact removed u•••@uci.edu · •••8839Contact removed (no phone or email listed)
    • UC San Diego Moores Cancer Center · La Jolla, United StatesContact added c•••@ucsd.edu · •••5354Contact added (no phone or email listed)
    • UCI Health Laguna Hills · Laguna Hills, United StatesContact removed u•••@uci.edu · •••8839Contact removed (no phone or email listed)
    • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United StatesContact removed u•••@uci.edu · •••8839Contact removed (no phone or email listed)
    • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
    • UC San Diego Medical Center - Hillcrest · San Diego, United StatesContact added r•••@health.ucsd.eduContact added (no phone or email listed)
    • Pacific Central Coast Health Center-San Luis Obispo · San Luis Obispo, United StatesContact person changed (no phone or email listed)
    • Mission Hope Medical Oncology - Santa Maria · Santa Maria, United StatesContact person changed (no phone or email listed)
    • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
    • Penrose-Saint Francis Healthcare · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • Rocky Mountain Cancer Centers-Penrose · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • Saint Francis Cancer Center · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Cancer Center Mercy · Durango, United StatesContact person changed (no phone or email listed)
    • Mercy Medical Center · Durango, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United StatesContact person changed (no phone or email listed)
    • Longmont United Hospital · Longmont, United StatesContact person changed (no phone or email listed)
    • Saint Mary Corwin Medical Center · Pueblo, United StatesContact person changed (no phone or email listed)
    • Rush-Copley Medical Center · Aurora, United StatesContact removed R•••@rush.edu · •••6212Contact removed (no phone or email listed)
    • Loyola University Medical Center · Maywood, United StatesContact person changed (no phone or email listed)
    • Rush-Copley Healthcare Center · Yorkville, United StatesContact removed C•••@rushcopley.com · •••6212Contact removed (no phone or email listed)
    • Greater Regional Medical Center · Creston, United StatesContact removed •••3305Contact removed (no phone or email listed)
    • CommonSpirit Saint Joseph Hospital - Bardstown · Bardstown, United StatesContact person changed (no phone or email listed)
    • …and 47 more sites
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05174169
Lead sponsor
NRG Oncology
Responsible party
Sponsor
First posted
Dec 30, 2021
Start date
Jul 8, 2022
Primary completion
Mar 10, 2029 (estimated)
Completion
Mar 10, 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Judy Langer
Contact
langerj@nrgoncology.org
412-339-5300
Langer
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion